Literature DB >> 17172608

Potential applications and limitations of proteomics in the study of neurological disease.

Yoshito Kinoshita1, Takuma Uo, Suman Jayadev, Gwenn A Garden, Thomas P Conrads, Timothy D Veenstra, Richard S Morrison.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17172608     DOI： 10.1001/archneur.63.12.1692

Source DB:  PubMed          Journal:  Arch Neurol        ISSN： 0003-9942


× No keyword cloud information.
  4 in total

1.  Protease inhibitor plasma concentrations associate with COVID-19 infection.

Authors:  Nicholas R Medjeral-Thomas; Anne Troldborg; Annette G Hansen; Rasmus Pihl; Candice L Clarke; James E Peters; David C Thomas; Michelle Willicombe; Yaseelan Palarasah; Marina Botto; Matthew C Pickering; Steffen Thiel
Journal:  Oxf Open Immunol       Date:  2021-07-07

2.  A density-based proteomics sample fractionation technology: folate deficiency induced oxidative stress response in liver and brain.

Authors:  Wenkui Lan; Jayita Guhaniyogi; Marc J Horn; Jun Q Xia; Beverly Graham
Journal:  J Biomol Tech       Date:  2007-09

3.  Quantitative proteomic analysis of mitochondria in aging PS-1 transgenic mice.

Authors:  You-Jun Fu; Shuling Xiong; Mark A Lovell; Bert C Lynn
Journal:  Cell Mol Neurobiol       Date:  2009-02-25       Impact factor: 5.046

4.  Genomic and Proteomic Biomarker Discovery in Neurological Disease.

Authors:  Rilee H Robeson; Andrew M Siegel; Travis Dunckley
Journal:  Biomark Insights       Date:  2008-02-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.